Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Debt (2022 - 2025)

Historic Total Debt for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Q3 2025 value amounting to $72.3 million.

  • Tarsus Pharmaceuticals' Total Debt rose 79.91% to $72.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.3 million, marking a year-over-year increase of 79.91%. This contributed to the annual value of $71.8 million for FY2024, which is 14093.7% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Total Debt of $72.3 million as of Q3 2025, which was up 79.91% from $72.1 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Total Debt high stood at $72.3 million for Q3 2025, and its period low was $19.2 million during Q1 2022.
  • Over the past 4 years, Tarsus Pharmaceuticals' median Total Debt value was $29.8 million (recorded in 2023), while the average stood at $43.2 million.
  • Its Total Debt has fluctuated over the past 5 years, first soared by 19088.47% in 2024, then skyrocketed by 76.98% in 2025.
  • Quarter analysis of 4 years shows Tarsus Pharmaceuticals' Total Debt stood at $19.4 million in 2022, then soared by 53.44% to $29.8 million in 2023, then soared by 140.94% to $71.8 million in 2024, then rose by 0.61% to $72.3 million in 2025.
  • Its last three reported values are $72.3 million in Q3 2025, $72.1 million for Q2 2025, and $72.0 million during Q1 2025.